BG
ARRY

BlackRock Group’s Array Biopharma Inc ARRY Stock Holding History

BlackRock Group’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$575K Sell
65,418
-132,114
-67% -$972K ﹤0.01% 2313
2016
Q3 		$1.33M Buy
197,532
+145,772
+282% +$564K ﹤0.01% 1877
2016
Q2 		$185K Sell
51,760
-36,941
-42% -$120K ﹤0.01% 2605
2016
Q1 		$262K Buy
88,701
+18,852
+27% +$56.5K ﹤0.01% 2484
2015
Q4 		$296K Buy
69,849
+35,339
+102% +$161K ﹤0.01% 2401
2015
Q3 		$158K Buy
34,510
+8,638
+33% +$51.2K ﹤0.01% 2584
2015
Q2 		$187K Buy
25,872
+5,701
+28% +$42.1K ﹤0.01% 2593
2015
Q1 		$148K Sell
20,171
-423,267
-95% -$3.01M ﹤0.01% 2575
2014
Q4 		$2.1M Buy
443,438
+7,926
+2% +$31.3K ﹤0.01% 1454
2014
Q3 		$1.55M Hold
435,512
– – ﹤0.01% 1538
2014
Q2 		$1.99M Hold
435,512
– – ﹤0.01% 1467
2014
Q1 		$2.05M Hold
435,512
– – ﹤0.01% 1557
2013
Q4 		$2.18M Buy
435,512
+20,243
+5% +$110K ﹤0.01% 1470
2013
Q3 		$2.58M Buy
415,269
+413,100
+19,046% +$2.45M ﹤0.01% 1337
2013
Q2 		$10K Buy
+2,169
New +$11.7K ﹤0.01% 2560

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

BlackRock Group's ARRY Position: Q4 2016 in Review

BlackRock Group reduced its Array Biopharma Inc (ARRY) stake by 67% in Q4 2016, selling an estimated $972K and leaving 65,418 shares worth $575K. The position accounts for ﹤0.01% of the portfolio, ranked #2313.

BlackRock Group first reported a position in ARRY in Q2 2013 and has held it in 15 quarters since. The position peaked at $2.58M in Q3 2013. 167 funds tracked by Wall St. Rank hold ARRY as of Q4 2016.

  • BlackRock Group held 65,418 shares of Array Biopharma Inc worth $575K as of Q4 2016.
  • BlackRock Group sold 132,114 Array Biopharma Inc shares in Q4 2016, an estimated $972K.
  • Array Biopharma Inc made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2313 holding.
  • BlackRock Group first reported a position in Array Biopharma Inc in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Array Biopharma Inc position peaked at $2.58M in Q3 2013.
  • 167 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.